At the Bio International Convention in Boston this month, MedCity signed a Memorandum of Understanding (MOU) with the Life Science Innovation Network Japan (LINK-J) to connect the life sciences ecosystems and promote commercialisation.

Following collaborative work with LINK-J over the past two years, including at the annual Bio Japan conference in Yokohama and working together on the Life Sciences Symposium in Nihonbashi in 2017, an MOU has been signed to promote open innovation in the life sciences through industry-academia-government collaboration. Based on the MOU, MedCity and LINK-J have agreed to provide a boost to commercialisation and industrialisation in life sciences and will mutually cooperate in creating new industries through open innovation over the next five years.

Akihiko Soyama, Director, President and Chief Executive Officer of LINK-J, added:

“I am delighted that we have reached the partnership with MedCity, at which renowned universities of the United Kingdom, where research on life science is conducted actively, collaborate with each other. We will contribute to the creation of new value through interactions between LINK-J and MedCity and will continue to make a contribution to the growth of the life science industry as a whole by deepening partnerships with a total of eight life science organizations in Japan and overseas.”

Sarah Haywood, CEO, MedCity said:

“We are pleased to have signed an MOU with LINK-J, aiding connections and support for UK life sciences companies and academics looking to work with the Japanese market, and vice versa.

“This MOU represents a strengthening of MedCity’s links with Japan and aims to provide a boost to commercialisation by mutual cooperation.

“We look forward to working closely with LINK-J to encourage UK-Japan collaborations across our life sciences ecosystems.”

ENDS